Samarium-153-EDTMP in the treatment of refractory rheumatoid arthritis.
We examined the preliminary safety and efficacy of intravenous samarium-153-EDTMP (Sm-153) in the treatment of refractory rheumatoid arthritis (RA). In an open-label sequential group comparison of 0.5, 1.0, and 2.0 mCi/kg, Sm-153 was administered as a single intravenous infusion to 24 patients with refractory disease. Across treatment doses, the frequency of American College of Rheumatology (ACR) 20% responses was 25%, 29%, 25%, and 33% at 2, 4, 8, and 12 weeks, respectively. Expected significant declines in absolute neutrophil count, hemoglobin, and platelet counts were observed with nadirs seen between 2-4 weeks. Sm-153, at doses of 0.5 and 1.0 mCi/kg, is well tolerated but minimally effective in the treatment of refractory RA as measured using ACR response criteria.
Mikuls
T R
TR
Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, USA.
Kahn
D
D
Utrie
P C
PC
Miller
S J
SJ
Koehnke
R
R
Goeckeler
W
W
Saag
K G
KG
D000293:Adolescent; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy*; D004351:Drug Resistance; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D010865:Pilot Projects; D011868:Radioisotopes; D012016:Reference Values; D012493:Samarium / Q000008:administration & dosage*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D011868:Radioisotopes; D012493:Samarium